{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-031899","form_type":"8-K","ticker":"DTIL","cik":"0001357874","company_name":"PRECISION BIOSCIENCES INC","filed_at":"2023-07-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.694498+00:00","generated_at":"2026-06-13T11:38:26.568285+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Precision BioSciences amends Prevail collaboration; milestones cut to $390-395M, cash runway to Q1 2025","bullets":["Preclinical and IND-enabling activities shifted to Prevail; manufacturing of initial clinical supply also Prevail's responsibility.","Maximum milestone payments per licensed product reduced from $420M to $390-395M reflecting changed cost sharing.","Prevail continues to fund development and commercialization; royalties and nomination fees unchanged.","Company expects existing cash, operational receipts and credit to fund operations through Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-031899","json":"https://secwatch.observer/filing/0000950170-23-031899.json","markdown":"https://secwatch.observer/filing/0000950170-23-031899.md","text":"https://secwatch.observer/filing/0000950170-23-031899.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357874/000095017023031899/0000950170-23-031899-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357874/000095017023031899/dtil-20230630.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T11:38:26.568285+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"72d7754008d02583cf634ac0472006596b88694c","claim":"PRECISION BIOSCIENCES INC amended A&R Development and License Agreement with Prevail Therapeutics Inc. valued at up to an aggregate of $390 million to $395 million per licensed product (effective 2023-06-30).","evidence_excerpt":"On June 30, 2023, Precision BioSciences, Inc. (the “Company”) entered into an amended and restated development and license agreement (the “A&R Development and License Agreement”) with Prevail Therapeutics Inc. (“Prevail”), a wholly owned subsidiary of Eli Lilly and Company (“Lilly”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1357874/000095017023031899/0000950170-23-031899-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Prevail Therapeutics Inc."},{"label":"Value","value":"up to an aggregate of $390 million to $395 million per licensed product"},{"label":"Effective","value":"2023-06-30"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}